ALX Oncology Holdings Inc. (ALXO) News
Filter ALXO News Items
ALXO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ALXO News From Around the Web
Below are the latest news stories about ALX ONCOLOGY HOLDINGS INC that investors may wish to consider to help them evaluate ALXO as an investment opportunity.
7 Small-Cap Stocks That Wall Street Loves for Good ReasonThe market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading |
ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate DevelopmentsPositive Clinical Trial Results and Public Offering Highlight the Quarter |
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. Third Quarter 2023 Highlights and Recent Developments Reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatme |
ALX Oncology Announces November Investor Conference ParticipationSOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in three upcoming investor conferences in November. 2023 UBS BioPharma ConferenceFormat: Fireside chat with analyst, Dr. Colin BristowDate: Wednesday, November 8thTime: 1:30 PM ESTLocation: Miami Beach, FLWebcast link: Availa |
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesSOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the u |
While institutions invested in ALX Oncology Holdings Inc. (NASDAQ:ALXO) benefited from last week's 74% gain, private equity firms stood to gain the mostKey Insights Significant control over ALX Oncology Holdings by private equity firms implies that the general public has... |
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and ModernaNovavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog. |
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & MoreRegulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector. |
ALX Oncology Announces Pricing of Public OfferingSOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology is selling 7,370,690 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchas |
ALX Oncology Announces Proposed Public OfferingSOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants in this offering will be sold by ALX Oncology. The proposed offering is subject to market and othe |